• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEF 14A filed by Mannatech Incorporated

    4/22/25 5:01:03 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email
    DEF 14A 1 a2025proxyadditionalmateri.htm DEF 14A Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a)
    of the Securities Exchange Act of 1934
    (Amendment No.    )
    Filed by the Registrant  x
    Filed by a Party other than the Registrant ☐
    Check the appropriate box:
    ☐Preliminary Proxy Statement☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    xDefinitive Additional Materials
    ☐Soliciting Material Pursuant to §240.14a-12
    Mannatech, Incorporated
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check the appropriate box):
    xNo fee required.
    oFee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
    (1)Title of each class of securities to which transaction applies:
       
    (2)Aggregate number of securities to which transaction applies:
       
    (3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
       
    (4)Proposed maximum aggregate value of transaction:
       
    (5)Total fee paid:
      
    oFee paid previously with preliminary materials.
    oCheck box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    (1)Amount Previously Paid:
    (2)Form, Schedule or Registration Statement No.:
    (3)Filing Party:
    (4)Date Filed:




    image.jpg



    image1.jpg

    Get the next $MTEX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    SEC Filings

    View All

    Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MANNATECH INC (0001056358) (Filer)

    8/12/25 5:13:35 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Mannatech Incorporated

    10-Q - MANNATECH INC (0001056358) (Filer)

    8/12/25 5:09:16 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Incorporated filed SEC Form 8-K: Leadership Update

    8-K - MANNATECH INC (0001056358) (Filer)

    7/24/25 4:17:35 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mannatech Reports Financial Results for Second Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2025. Second Quarter Results Net sales for the quarter ended June 30, 2025 were $25.7 million, as compared to $27.7 million for the same period in 2024, a decrease of $2.1 million, or 7.4%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.8 million, or 6.5%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    8/12/25 5:18:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Promotion of Peter Griscom to Chief Operating Officer

    Mannatech, Incorporated (NASDAQ: MTEX) announces the promotion of Peter Griscom to Chief Operating Officer of Mannatech Incorporated (the "Company") effective July 1, 2025. Peter Griscom brings more than 10 years of experience in the direct selling channel and has extensive experience in working in the consumer goods space, including launching, leading, and restructuring companies while creating efficiencies in manufacturing, sales, and marketing. Prior to his promotion, Mr. Griscom served as the Company's senior vice president of global operations since August 21, 2024 and prior to that served as the senior vice president of product, innovation, & supply chain from July 3, 2023 through A

    6/26/25 2:11:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Results of Annual Shareholders' Meeting

    Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 3, 2025. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting, and James Clavijo, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2024. There were 1,900,930 outstanding shares of Mannatech's common stock as of April 8, 2025 entitled to vote and 1,478,342 shares, or approximately 77.8% represented at the Meeting, either i

    6/5/25 2:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Chief Financial Officer Clavijo James

    4/A - MANNATECH INC (0001056358) (Issuer)

    8/28/25 4:22:11 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form 4 filed by General Counsel Barta Erin Kemmler

    4/A - MANNATECH INC (0001056358) (Issuer)

    8/28/25 4:22:03 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form 4 filed by President and CEO Fredrick Landen Granvel

    4/A - MANNATECH INC (0001056358) (Issuer)

    8/28/25 4:21:55 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    9/10/24 5:45:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    View All

    Mannatech Announces Results of Annual Shareholders' Meeting

    Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 3, 2025. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting, and James Clavijo, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2024. There were 1,900,930 outstanding shares of Mannatech's common stock as of April 8, 2025 entitled to vote and 1,478,342 shares, or approximately 77.8% represented at the Meeting, either i

    6/5/25 2:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

    Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

    11/26/24 4:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

    Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

    7/1/24 5:46:00 PM ET
    $AEZS
    $MTEX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $MTEX
    Financials

    Live finance-specific insights

    View All

    Mannatech Reports Financial Results for Second Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2025. Second Quarter Results Net sales for the quarter ended June 30, 2025 were $25.7 million, as compared to $27.7 million for the same period in 2024, a decrease of $2.1 million, or 7.4%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.8 million, or 6.5%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    8/12/25 5:18:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for First Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    5/13/25 6:06:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Third Quarter 2024

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowi

    11/12/24 4:48:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Mannatech Incorporated

    SC 13G - MANNATECH INC (0001056358) (Subject)

    11/1/24 11:44:29 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    1/13/23 11:03:46 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    2/7/22 6:32:28 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care